相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology
Martin C. Michel et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Do overactive bladder symptoms and their treatment-associated changes exhibit a normal distribution? Implications for analysis and reporting
Marjan Amiri et al.
NEUROUROLOGY AND URODYNAMICS (2020)
Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
Martin C. Michel et al.
FRONTIERS IN PHARMACOLOGY (2020)
Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment A retrospective multicenter study
Myungsun Shim et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2020)
Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
Howard B. Goldman et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2019)
Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women A Systematic Review and Meta-analysis
W. Stuart Reynolds et al.
OBSTETRICS AND GYNECOLOGY (2015)
Factors Associated With Dose Escalation of Fesoterodine for Treatment of Overactive Bladder in People >65 Years of Age: A Post Hoc Analysis of Data From the SOFIA study
Adrian Wagg et al.
NEUROUROLOGY AND URODYNAMICS (2015)
An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material
T. Schneider et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials
J. J. Wyndaele et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
Ji-Youn Chun et al.
INTERNATIONAL NEUROUROLOGY JOURNAL (2014)
Overactive bladder in the vulnerable elderly
Gillian F. Wolff et al.
RESEARCH AND REPORTS IN UROLOGY (2014)
Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)
Linda Cardozo et al.
BJU INTERNATIONAL (2013)
A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management-a Systematic Review and Meta-analysis
Jean-Nicolas Cornu et al.
EUROPEAN UROLOGY (2012)
Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation
Linda Cardozo et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2012)
The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms
David R. Staskin et al.
JOURNAL OF UROLOGY (2012)
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study
Jean-Jacques Wyndaele et al.
BJU INTERNATIONAL (2011)
Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example
Martin C. Michel et al.
EUROPEAN UROLOGY SUPPLEMENTS (2011)
Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study
Matthias Oelke et al.
WORLD JOURNAL OF UROLOGY (2011)
Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
T. Schneider et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
Linda Cardozo et al.
BMC UROLOGY (2010)
Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?
Lambertus P. W. Witte et al.
CURRENT OPINION IN UROLOGY (2009)
Nocturia: A non-specific but important symptom of urological disease
Tim Schneider et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy
Henricus G. Ruhe et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use - A 12-week, open-label, post-marketing surveillance study
Martin C. Michel et al.
DRUG SAFETY (2008)
A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
Giacomo Novara et al.
EUROPEAN UROLOGY (2008)
Physiological and pathological regulation of the autonomic control of urinary bladder contractility
Martin C. Michel et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Fesoterodine dose response in subjects with overactive bladder syndrome
Vik Khullar et al.
UROLOGY (2008)
Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors
Elfaridah P. Frazier et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
Actions of two main metabolites of propiverine (M-1 and m-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes
Hai-Lei Zhu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients
Martin C. Michel et al.
NEUROUROLOGY AND URODYNAMICS (2007)
Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study
ML Ancelin et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms
Jules H. Schagen van Leeuwen et al.
EUROPEAN UROLOGY (2006)
Propiverine hydrochloride immediate and extended release: Comparison of efficacy and tolerability in patients with overactive bladder
K.-P. Juenemann et al.
UROLOGIA INTERNATIONALIS (2006)
Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction
M Wuest et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder
MC Michel et al.
EUROPEAN UROLOGY (2005)
An investigation of dose titration with darifenacin, an M3-selective receptor antagonist
W Steers et al.
BJU INTERNATIONAL (2005)
Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle
AG Fenech et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2004)
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder
L Cardozo et al.
JOURNAL OF UROLOGY (2004)
分享论文
